INTEGRAL DIAGNOSTICS LIMITED (IDX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

IDX - INTEGRAL DIAGNOSTICS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Index: ASX300 | ALL-ORDS

Integral Diagnostics is an Australian healthcare services company providing diagnostic imaging services to medical practitioners in Australia and New Zealand. It has been a listed company since 2015.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$3.92

20 May
2022

0.120

OPEN

$3.81

3.16%

HIGH

$3.95

747,560

LOW

$3.79

TARGET
$4.46

+0.03 change from previous day

13.8% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
ELX . PGC . AHZ . COH . FPH . IPD . LHC . NAN . RMD . SOM . HLA . MX1 . CAT . VHT . ONE . PME . CSX . 4DX . BRN . EMV . UBI . LDX . RAP . RVA . MEB . IME . PCK . CMP . CYC . IMR . VTI . OVN . EYE . CGS . CU6 . TRJ . EBR . AT1 . CBL .
FNARENA'S MARKET CONSENSUS FORECASTS
IDX: 1
Title FY20
Actual
FY21
Actual
FY22
Forecast
FY23
Forecast
EPS (cps) xxx 15.6 14.0 xxx
DPS (cps) xxx 12.3 9.6 xxx
EPS Growth xxx 27.1% - 10.3% xxx
DPS Growth xxx 31.6% - 22.4% xxx
PE Ratio xxx N/A 28.1 xxx
Dividend Yield xxx N/A 2.4% xxx
Div Pay Ratio(%) xxx 79.1% 68.5% xxx

Dividend yield today if purchased 3 years ago: 3.98%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

3.14

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 01/03 - ex-div 4c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2022 FactSet UK Limited. All rights reserved
Title 201620172018201920202021
EPS Basic xxxxxxxxxxxxxxx15.6
DPS All xxxxxxxxxxxxxxx12.3
Sales/Revenue xxxxxxxxxxxxxxx348.8 M
Book Value Per Share xxxxxxxxxxxxxxx126.5
Net Operating Cash Flow xxxxxxxxxxxxxxx69.6 M
Net Profit Margin xxxxxxxxxxxxxxx8.96 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201620172018201920202021
Return on Capital Employed xxxxxxxxxxxxxxx12.95 %
Return on Invested Capital xxxxxxxxxxxxxxx6.07 %
Return on Assets xxxxxxxxxxxxxxx5.06 %
Return on Equity xxxxxxxxxxxxxxx12.95 %
Return on Total Capital xxxxxxxxxxxxxxx8.95 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx31.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.6

No. Of Recommendations

5
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Credit Suisse

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

3

xxxxx-xxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

19/05/2022

1

Buy

$4.80

22.45%

Following Integral Diagnostics' $31m acquisition of Auckland-based Horizon Radiology, Citi has increased its earnings per share forecasts 2% for FY23 and FY24, noting the purchase is in line with company strategy and will complement its existing Auckland footprint. The purchase brings Integral Diagnostics' acquisition spend to $125m since February.

Citi also notes covid-related surgery delays and cancellations in the first quarter look likely to heavily impact on business in the second half, but suggests the market look through this noting historical growth is possible as the company addresses a backlog.

The Buy rating is retained and the target price increases to $4.80 from $4.70.

FORECAST
Citi forecasts a full year FY22 dividend of 11.00 cents and EPS of 14.20 cents.
Citi forecasts a full year FY23 dividend of 15.50 cents and EPS of 22.30 cents.

Macquarie

xx/xx/xxxx

1

xxxxxxx xx xxxxxxxxxx xxxx xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

IDX STOCK CHART